Loading clinical trials...

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori

Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population

NCT02693574•Damascus Hospital

View on ClinicalTrials.gov

Summary

Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the Eradication of Helicobacter Pylori in Syrian population

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1-Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods: I-Positive rapid urease test (CLOtest). II-Histologic evidence of H. pylori by modified Giemsa staining. III-Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.

Exclusion Criteria

•1. Children and teenagers aged less than 18 years.
•2. Previous eradication treatment for H. pylori.
•3. Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.
•4. History of gastrectomy.
•5. Gastric malignancy, including adenocarcinoma and lymphoma,
•6. Previous allergic reaction to antibiotics (Amoxicillin, Clarithromycin, Levofloxacin) and prompt pump inhibitors (Es-omeprazole).
•7. Contraindication to treatment drugs.
•8. Pregnant or lactating women.
•9. Severe concurrent disease.
•10. Liver cirrhosis.
+2 more criteria

Locations (1)

Damascus Hospital

Damascus, Syria

Key Dates

Start Date

December 1, 2015

Primary Completion Date

January 28, 2017

Completion Date

May 31, 2017

Last Updated

March 21, 2017

Enrollment

ACTUAL participants

Conditions

Helicobacter Pylori Gastrointestinal Tract Infection

Interventions

Clarithromycin

DRUG

Levofloxacin

DRUG

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT07293910

HELICOBACTER PYLORI INFECTIONSHelicobacter Infection+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 21, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions